Compugen Ltd. (NASDAQ:CGEN) shares saw unusually-high trading volume on Monday . Approximately 455,900 shares changed hands during mid-day trading, an increase of 199% from the previous session’s volume of 152,372 shares.The stock last traded at $7.41 and had previously closed at $7.05.

CGEN has been the subject of several recent analyst reports. FBR & Co reissued a “buy” rating on shares of Compugen in a report on Wednesday, June 22nd. Zacks Investment Research raised Compugen from a “sell” rating to a “hold” rating in a report on Tuesday, August 2nd. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Compugen presently has a consensus rating of “Buy” and an average target price of $10.25.

The stock has a 50-day moving average of $6.80 and a 200 day moving average of $6.40. The stock’s market capitalization is $377.23 million.

Compugen (NASDAQ:CGEN) last announced its quarterly earnings data on Tuesday, August 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.04. Equities analysts predict that Compugen Ltd. will post ($0.56) EPS for the current year.

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.